Role of 18F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for 177Lu-DOTATATE peptide receptor radionuclide therapy
Quantitative baseline and mid-treatment <sup>18</sup>F-AlF-NOTATATE PET/CT-derived parameters possess value in predicting PRRT response. An interim-to-baseline PET-derived lesion SUV<sub>max</sub> ratio of ≤1.25 can effectively predict neuroblastoma response to PRRT.
Authors
- Di Zuo (ORCID: https://orcid.org/0000-0002-1803-7878)
- Jingfu Wang
- Han Wang (ORCID: https://orcid.org/0000-0001-8042-1232)
- Yuxuan Liu (ORCID: https://orcid.org/0000-0003-4426-9290)
- Yingying Sun (ORCID: https://orcid.org/0000-0003-2633-5784)
- Xiaorong Sun (ORCID: https://orcid.org/0000-0002-3266-3023)
- Fei Zheng (ORCID: https://orcid.org/0000-0003-2407-5149)
Institutions
- Qingdao University (CN)
- Shandong Tumor Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-08-28
- DOI
- https://doi.org/10.3389/fmed.2025.1615136
- Citations
- 1
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China